MRNA Jumps As FDA Clears New Flu Vaccine mFLUSIVA

Moderna Inc. stocks have been trading up by 128.27 percent amid bullish sentiment on its advancing mRNA vaccine pipeline.

Spot the Next Big Runner

Click Here for a Millionaire's POV on Trading MRNA

SUBSCRIBE FOR ALERTS

JOIN 50,000+ ACTIVE TRADERS

Key Takeaways For MRNA Traders

FDA approval of mFLUSIVA gives Moderna a fourth U.S. product and targets a 2026–27 flu-season launch, expanding beyond its COVID cash cow.
Q2 2026 results for MRNA showed a narrower net loss and slight revenue growth, edging past Wall Street expectations and tightening expense guidance.
Management kept a 10% 2026 revenue growth target, trimmed cost-of-sales to $1.7B, and plans an even U.S./international revenue split.
A new Phase 1 Ebola-strain vaccine trial and CEPI’s up-to-$50M backing highlight continued platform expansion for Moderna.
Citi and Goldman lifted MRNA price targets to $60 and $67, but stayed Neutral as heavy R&D spend and losses continue.

Live Update At 12:32:27 EDT: On Wednesday, August 19, 2026 Moderna Inc. stock [NASDAQ: MRNA] is trending up by 128.27%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

MRNA just delivered the kind of chart that wakes traders up. After grinding in the mid-$50s and $60s for weeks, the stock exploded from a prior close near $63 to an intraday high above $163, finishing around $143.8. That is a massive range expansion day and a classic momentum breakout for active trading.

Under the hood, Moderna is still a loss-making story. Q2 2026 revenue was about $1.94B over the last twelve months, yet profit margins are deeply negative, with EBIT margin around -139% and free cash flow for the quarter at roughly -$563M. MRNA posted a Q2 loss of $1.97 per share, but that was slightly better than the expected $2.01 loss, so it counted as an earnings “beat.”

More Breaking News

The balance sheet remains a key support. Moderna holds roughly $5.14B in cash and short-term investments, with a current ratio of 2.3 and low leverage (total debt-to-equity only 0.18). For traders, that means MRNA has runway to keep funding its pipeline even while it burns cash. The combination of strong liquidity, narrowing losses, and a violent price breakout puts MRNA firmly back on momentum watchlists.

Why Traders Are Watching MRNA After mFLUSIVA Approval

The main catalyst lighting up MRNA is clear: the FDA just approved Moderna’s mFLUSIVA (mRNA-1010) seasonal flu vaccine for adults 50+. This is Moderna’s fifth global product and its fourth FDA-approved product, with a U.S. launch targeted for the 2026–27 flu season. For traders, that’s not tomorrow’s revenue, but it is today’s de-risking of a major new franchise.

This flu approval shifts the Moderna story away from being a one-hit COVID wonder. It confirms that the mRNA platform can win repeat regulatory decisions in a big, recurring market like seasonal influenza. Another key angle: regulators in Australia, Canada, and Europe are already reviewing mFLUSIVA. That lines up directly with management’s plan for 2026 revenue to be split 50/50 between the U.S. and the rest of the world. MRNA now has a clearer path to that international mix.

At the same time, the tape shows traders reacting to more than just one headline. MRNA reported a narrower Q2 loss, slight year-over-year revenue growth, and beat consensus on both revenue and EPS. The stock even popped more than 3% after the print, before this bigger mFLUSIVA surge. Management also lowered its FY26 cost-of-sales outlook to $1.7B from $1.8B and reaffirmed a 10% revenue growth target from 2025 levels. Those are not blowout growth numbers, but they send a signal of tightening execution.

Pipeline news adds another layer. Moderna kicked off a Phase 1 trial in Canada for mRNA-1469, targeting Bundibugyo ebolavirus, with up to $50M in support from CEPI and parallel manufacturing to accelerate later trials if data cooperate. That is early stage and not a near-term moneymaker, yet it shows the platform’s reach beyond COVID and flu. Still, traders should remember the risk side: a key norovirus Phase 3 study recently failed to hit early success criteria, reminding everyone that not every mRNA bet will pay.

Wall Street’s stance on MRNA helps frame expectations. Citi raised its target from $41 to $60, and Goldman Sachs moved from $49 to $67; UBS also nudged its target to $50. Yet all three remain Neutral, and the broader consensus sits around a Hold with average targets in the low-to-mid $50s, not far from where the stock traded before this spike. That tells traders MRNA was priced for skepticism, and the flu approval plus earnings beat are now forcing models higher.

Conclusion

For active traders, MRNA is back in play as a high-volatility, news-driven name anchored by a real commercial pipeline. The FDA green light for mFLUSIVA validates Moderna’s push into seasonal flu and adds a future revenue stream for the 2026–27 season and beyond. Q2 numbers show a business still deep in the red, with EBITDA and free cash flow both sharply negative, but the loss curve is bending in the right direction while cash reserves remain strong.

At the same time, Moderna is not easing off the gas. Management expects 2026 R&D expenses of about $2.9B and kept capital expenditures at $200M–$300M. That level of spend, paired with new programs like the Bundibugyo ebolavirus vaccine and ongoing oncology and rare disease trials, tells traders this is still a story about long-term platform optionality, not near-term earnings stability. The failed norovirus study underlines the binary nature of biotech, so chasing MRNA means accepting real downside risk when data disappoint.

Wall Street’s Neutral stance, even as price targets grind higher, gives a useful guardrail for trading psychology. The big banks are growing more constructive, but they are not calling MRNA cheap. That usually sets up a battleground tape where headlines and technical levels matter more than smooth valuation models.

This article is for educational and research purposes only, but the trading mindset applies: as Tim Sykes loves to say, “patterns repeat, but traders don’t always recognize them.” As Tim Bohen, lead trainer with StocksToTrade says, “There’s a pattern in everything; you just have to stick around long enough to see it.”, and that perspective lines up well with how MRNA tends to trade around catalysts. With MRNA, the pattern is clear—big catalyst, big volume, big range. The real edge comes from staying nimble, respecting the volatility, and knowing exactly where you will cut losses if the story flips.

This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.

Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.

Check out our quick startup guide for new traders!

Ready to build your watchlists? Check out these curated lists:

Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.

Start Your Trial Now!